You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物-B(01801.HK):公司先舊後新發行9700萬股 淨籌約為23.51億港元
格隆匯 10-04 08:20

格隆匯10月4日丨信達生物-B(01801.HK)公佈,於2019年10月4日,公司、賣方,公司董事會主席俞德超及Great Biono及配售代理訂立配售及認購協議,據此,(a)賣方已共同及個別同意委任配售代理,及配售代理已個別但非共同同意作為代理行事,以作為賣方的配售代理促使承配人按配售價或自行按配售價認購9700萬股銷售股份;及(b)賣方已個別同意認購,及公司已同意按認購價向賣方發行9700萬股新股份。

公告顯示,銷售股份的數目相當於:(a)於公告日期已發行股份總數的約8.37%;及(b)於完成認購事項後經擴大股本的約7.73%。配售價相當於聯交所所報收市價每股26.40港元折讓約6.82%。

公告稱,得款項淨額將約為23.51億港元。公司擬將其全球發售所得款項中約20.51億港元用於撥資正在進行及計劃中的四大核心產品的臨牀試驗、註冊備案的準備事宜及計劃的商業化推出,以及約7.888億港元用於撥資其他管線候選藥物的相同事宜。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account